Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse S. SaleR. G. TunstallA. J. Gescher Preclinical Studies 24 February 2006 Pages: 459 - 464
Studies on reaction of amino acids and triplet thioxanthone derivatives by laser flash photolysis Hongping ZhuWenfeng WangSide Yao Preclinical Studies 31 March 2006 Pages: 465 - 470
Antiangiogenic effect of 2-benzoyl–phenoxy acetamide in EAT cell is mediated by HIF-1α and down regulation of VEGF of in-vivo B. T. PrabhakarShaukath Ara KhanumBharathi P. Salimath OriginalPaper 31 March 2006 Pages: 471 - 478
Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats Kumaraswami DeepthaMuthaiyan KamaleeswariNamasivayam Nalini OriginalPaper 31 March 2006 Pages: 479 - 488
MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53 De-Hua YuJames MacDonaldQi-Xiang Li Preclinical Studies 05 April 2006 Pages: 489 - 498
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies Jill GilbertMichael A. CarducciRoss Donehower Phase I Studies 21 June 2006 Pages: 499 - 508
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS) Revathi SuppiahLaura WoodGeorge T. Budd Phase I Studies 21 June 2006 Pages: 509 - 514
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study Robert P. WhiteheadSheryl McCoyJames L. Abbruzzese Phase II Studies 11 May 2006 Pages: 515 - 520
Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma C. BollingT. GraefeA.-R. Hanauske Phase II studies 11 May 2006 Pages: 521 - 527
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145 Michael J. KovacsDonna E. ReeceElizabeth Eisenhauer Phase II Studies 21 June 2006 Pages: 529 - 535
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study James H. DoroshowSheryl McCoyJames L. Abbruzzese Phase II Studies 10 July 2006 Pages: 537 - 542
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma Ellen A. RonnenG. Varuni KondaguntaRobert J. Motzer Phase II Studies 10 July 2006 Pages: 543 - 546